GSK agreed to license Hutchmed’s HMPL-A830, a dual-action antibody-targeted therapy conjugate designed to combine an EGFR-targeting antibody with a KRAS inhibitor payload. The deal, valued at up to $1.295 billion including milestones and royalties, includes $110 million upfront for the preclinical asset. The transaction further expands GSK’s participation in next-generation antibody formats, with the company planning early clinical development through its licensed territories while Hutchmed retains rights in Mainland China and other specified regions. GSK indicated initial development focus across colorectal, pancreatic, and lung cancer. Strategically, the structure underscores how large pharmas are moving beyond traditional monotherapy into multi-hit constructs aimed at addressing tumor signaling redundancy between EGFR and KRAS pathways.